Cargando…

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study

INTRODUCTION: Osilodrostat decreases cortisol production by inhibiting 11β-hydroxylase, which increases adrenal hormones proximal to the blockade. Here, we describe these effects of osilodrostat and associated adverse events (AEs). The efficacy and safety of osilodrostat in patients with Cushing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleseriu, Maria, Biller, Beverly M K, Shimatsu, Akira, Newell-Price, John, Tabarin, Antoine, Vila, Greisa, Piacentini, Andrea, Pedroncelli, Alberto M, Pivonello, Rosario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625140/ http://dx.doi.org/10.1210/jendso/bvac150.1136

Ejemplares similares

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
por: Snyder, Peter J, et al.
Publicado: (2023)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

PMON162 Osilodrostat Provides Sustained Clinical Benefits and Improves Health-Related Quality of Life in Patients with Cushing's Disease: Results from the Phase III LINC 4 Study
por: Feelders, Richard, et al.
Publicado: (2022)

Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension
por: Fleseriu, Maria, et al.
Publicado: (2022)

Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)
por: Gadelha, Mônica, et al.
Publicado: (2021)

OR27-3 Long-Term Results from the Phase III LINC 4 Study: Osilodrostat Maintained Normal Mean Urinary Free Cortisol in Patients with Cushing's Disease, with a Favorable Safety Profile
por: Auchus, Richard J, et al.
Publicado: (2022)

ODP340 NOVEL THERAPY OSILODROSTAT AS AN OPTION FOR RECURRENT CUSHING'S DISEASE
por: Marin, Luis Madera, et al.
Publicado: (2022)

LBMON177 Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study
por: Ioachimescu, Adriana Gabriela, et al.
Publicado: (2022)

LBMON176 Management, Safety, And Efficacy Of Osilodrostat Treatment In US Patients With Non-pituitary Cushing's Syndrome: Results From The ILLUSTRATE Study
por: Auchus, Richard Joseph, et al.
Publicado: (2022)

SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM)
por: Fleseriu, Maria, et al.
Publicado: (2019)

SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease
por: Savage, Martin, et al.
Publicado: (2019)

PMON149 Identification of TR4 Modulators for Treatment of Cushing Disease.
por: Zhang, Dongyun, et al.
Publicado: (2022)

PMON102 Utility of the Desmopressin Stimulation Test to Detect Cyclic Cushing's Disease
por: Elenius, Henrik, et al.
Publicado: (2022)

PMON87 A Case of Mineralocorticoid Induced Hypertension Secondary to Cushing's Syndrome
por: Abideen, Zain U, et al.
Publicado: (2022)

PMON73 Lipid profile in patients with Cushing's syndrome and the impact of surgical treatment
por: Varghese, Ron, et al.
Publicado: (2022)

Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)
por: Fleseriu, Maria, et al.
Publicado: (2022)

PMON94 Collision tumor with Rathke cleft cyst and co existing Cushing's disease
por: Mittal, Ashima, et al.
Publicado: (2022)

SAT-443 Osilodrostat Has No Clinically Relevant Effect on the Pharmacokinetic (PK) Profile of a Monophasic Oral Contraceptive in Healthy Females Receiving Cortisol Replacement Therapy
por: Breitschaft, Astrid, et al.
Publicado: (2019)

RF01 | PMON167 Isolated Cushing's Disease Associated With Rare Germline SDHx Variants
por: Chittiboina, Prashant, et al.
Publicado: (2022)

PMON93 Adenoma Size & Inferior Petrosal Sinus Sampling in Cushing's Disease Diagnosis - Smoke & Mirrors?
por: Hashmi, Hiba, et al.
Publicado: (2022)

Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2021)

PMON123 Diagnostically Challenging Case of Cushing's Syndrome from a Pancreatic Neuroendocrine Tumor Treated with Radiofrequency Ablation
por: Gugger, Aristea Sideri, et al.
Publicado: (2022)

MON-318 Acute, Life-Threatening and Perioperative Complications in Cushing’s Syndrome: Predictors and Outcomes
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2020)

Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples
por: Fleseriu, Maria, et al.
Publicado: (2022)

PMON98 High-dose dexamethasone suppression test in ACTH-dependent Cushing's syndrome: Lessons learned on the lack of cortisol suppression
por: Ali, Roshaneh, et al.
Publicado: (2022)

PMON152 In Patients with Cushing's Disease and a Visible Tumor on MRI, IPSS does not Add to the Accuracy of Predicting Tumor Lateralization
por: Lundholm, Michelle D, et al.
Publicado: (2022)

PMON80 Case of Cushing's Disease That Presented as Diabetic Ketoacidosis and Successfully Treated With Stereotactic Radiosurgery During the COVID-19 Pandemic
por: Cadeliña, Jekrylei, et al.
Publicado: (2022)

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

PMON66 A Systematic Literature Review to Evaluate Extended Dosing Intervals in the Pharmacological Management of Acromegaly
por: Fleseriu, Professor Maria, et al.
Publicado: (2022)

THU019 Osilodrostat As An Emergency Alternative For Hypercortisolism In A Patient With An Impaired Liver Function
por: Minasyan, Mari, et al.
Publicado: (2023)

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

PMON165 Favorable Liver Safety Profile of the Selective Glucocorticoid Receptor Modulator Relacorilant in Healthy and Hepatically Impaired Adults and in Patients with Cushing Syndrome
por: Moraitis, Andreas, et al.
Publicado: (2022)

Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study
por: Zacharieva, Sabina, et al.
Publicado: (2021)

PMON75 Unilateral Galactorrhea in an Elderly Male
por: Monsour, Elio, et al.
Publicado: (2022)

Antisense Oligonucleotides as a Novel Therapy for Cushing’s Disease
por: Eltumi, Hanan, et al.
Publicado: (2021)

SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas
por: Terzolo, Massimo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pnslogdl8p507tj67877gfdopi